Currently, drugs targeting PD-L1 are being tested in clinical trials against multiple cancer types, including colorectal cancer (CRC) [83], non-small cell lung cancer (NSCLC) [84, 85], and urothelial carcinoma [86]. The gene discussed is CD274; the disease is cancer.